Alterity Therapeutics (NASDAQ: ATHE) highlights MSA program at key May 2026 medical meetings

Rhea-AI Filing Summary

Alterity Therapeutics Limited reports that presentations on its development program for Multiple System Atrophy (MSA) will be delivered at several medical conferences in May 2026. These include the International Society for Magnetic Resonance in Medicine annual meeting, the Movement Disorder Society of Australia and New Zealand meeting, and the MSA Symposium 2026.

The company describes itself as a clinical stage biotechnology firm focused on disease modifying therapies for MSA and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA. Its lead asset, ATH434, has shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial and positive data in an open label Phase 2 trial in advanced MSA.

Key Figures

Phase 3 trial stage: Phase 3 pivotal trial Phase 2 trial design: Randomized, double-blind, placebo-controlled Open label Phase 2: Positive data reported +2 more

5 metrics

Phase 3 trial stage Phase 3 pivotal trial Planned initiation in Multiple System Atrophy

Phase 2 trial design Randomized, double-blind, placebo-controlled ATH434 Phase 2 clinical trial in MSA

Open label Phase 2 Positive data reported ATH434 trial in participants with advanced MSA

Conference timing May 2026 Multiple medical conferences featuring MSA presentations

Investor relations phone +1 (415) 203-6386 Investor Relations Advisory Solutions contact

Key Terms

Multiple System Atrophy (MSA), Phase 3 pivotal trial, randomized, double-blind, placebo-controlled, open label Phase 2 clinical trial, +1 more

5 terms

Multiple System Atrophy (MSA) medical

"presentations related to the Company’s development program in Multiple System Atrophy (MSA)"

A progressive neurological disorder in which brain cells that control movement, balance and automatic body functions (like blood pressure, bladder control and digestion) gradually fail, causing symptoms such as poor coordination, stiffness, fainting and urinary problems. Investors care because the condition drives demand for diagnostic tests, therapies and long-term care solutions; successful clinical trials, regulatory approvals or setbacks can materially affect the valuation and revenue prospects of companies developing treatments, devices or related services.

Phase 3 pivotal trial medical

"Alterity is preparing to initiate a Phase 3 pivotal trial in MSA"

A phase 3 pivotal trial is the large, final clinical study that tests whether a new drug or medical treatment works and is safe enough for regulators to approve it for widespread use. Think of it as the full-scale dress rehearsal before a product launches: positive results can unlock regulatory approval and big commercial upside, while failures can halt a program and significantly affect investor value.

randomized, double-blind, placebo-controlled medical

"has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial"

A "randomized, double-blind, placebo-controlled" process is a method used to test the effectiveness of a new treatment or intervention. Participants are randomly assigned to different groups, with one receiving the real treatment and the other a fake version, called a placebo. Neither the participants nor the researchers know who is receiving which, which helps ensure unbiased results. For investors, this rigorous approach increases confidence that the findings are accurate and not influenced by guesswork or bias.

open label Phase 2 clinical trial medical

"reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA"

forward-looking statements regulatory

"This press release contains "forward-looking statements" within the meaning of section 27A"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Form 6-K: How Foreign Companies Report to the SEC →

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Alterity Therapeutics Limited

(Name of Registrant)

Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

The following exhibits are submitted:

99.1 Alterity to Deliver Presentations at May Medical Meetings

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Alterity Therapeutics Limited
	By:	/s/ Julian Babarczy
		Julian Babarczy
		Chairman

Date: May 7, 2026

2

Exhibit 99.1

Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 7 May 2026: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that presentations related to the Company’s development program in Multiple System Atrophy (MSA) will be delivered at multiple medical conferences in May 2026.

The International Society for Magnetic Resonance in Medicine 2026 ISMRM and ISMRT Annual Meeting and Exhibition

● Title: Quantitative Susceptibility Mapping Detects Progressive Iron Accumulation in Early MSA (Abstract #03335)

● Type: Oral Presentation

● Presenter: Paula Trujillo, PhD, Research Assistant Professor, Department of Neurology, Vanderbilt University Medical Center

● Date/Time: Tuesday, May 12, 2026, 16:00-17:50 local time

● Location: Cape Town, South Africa

Movement Disorder Society of Australia and New Zealand (MDSANZ) Scientific Meeting

● Title: Results from a Randomized, Double-Blind, Placebo-Controlled Study of ATH434 in MSA using CSF NfL as a Covariate

● Type: Poster Presentation

● Presenter: Daniel Claassen, M.D., M.S., Professor of Neurology at Vanderbilt University Medical Center and Chief Medical Advisor for Alterity

● Conference Dates: May 15-17, 2026

● Location: Sydney, Australia

MSA Symposium 2026

● Title: ATH434 Clinical Update and Phase 3 Planning

● Type: Oral Presentation

● Presenter: David Stamler, M.D., CEO of Alterity Therapeutics

● Date/Time: Monday, May 18, 2026, 16.15-17.00 local time

● Location: London, UK

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at https://alteritytx.com.

Authorisation & Additional information

This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

Contacts:

Investors:

Elyse Shapiro

ir@alteritytx.com

Remy Bernarda

Investor Relations Advisory Solutions

ir@alteritytx.com

+1 (415) 203-6386

Media

Casey McDonald

Tiberend Strategic Advisors, Inc.

cmcdonald@tiberend.com

+1 (646) 577-8520

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

FAQ

What did Alterity Therapeutics (ATHE) announce in its May 2026 Form 6-K?

Alterity Therapeutics announced that presentations on its Multiple System Atrophy (MSA) program will be delivered at several medical conferences in May 2026. The update highlights ongoing clinical development of lead candidate ATH434 and the company’s focus on disease modifying therapies for neurodegenerative disorders.

Which medical conferences will feature Alterity Therapeutics’ MSA research in May 2026?

Alterity’s MSA program will be presented at the ISMRM and ISMRT Annual Meeting and Exhibition, the Movement Disorder Society of Australia and New Zealand Scientific Meeting, and the MSA Symposium 2026. These venues showcase clinical and scientific data to the neurology and movement disorders communities.

What is Alterity Therapeutics’ lead drug candidate ATH434 for MSA?

ATH434 is Alterity’s lead asset targeting Multiple System Atrophy, a rare, rapidly progressive neurodegenerative disease. It has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial, and produced positive data in an open label Phase 2 trial in participants with advanced MSA.

What stage of development is Alterity Therapeutics’ MSA program currently in?

Alterity describes itself as a clinical stage biotechnology company and is preparing to initiate a Phase 3 pivotal trial in Multiple System Atrophy. This follows clinically meaningful Phase 2 results and open label Phase 2 data for ATH434 in participants with early and advanced MSA, respectively.

What diseases is Alterity Therapeutics (ATHE) focused on treating?

Alterity focuses on developing disease modifying therapies for neurodegenerative conditions, particularly Multiple System Atrophy and related Parkinsonian disorders. The company also operates a drug discovery platform that generates patentable chemical compounds targeting underlying neurological disease pathology, supporting a broader neurodegeneration pipeline beyond its lead MSA program.

Where is Alterity Therapeutics based and how can investors contact the company?

Alterity is based in Melbourne, Australia, and San Francisco, California, USA. Investor contacts include Elyse Shapiro and Remy Bernarda via ir@alteritytx.com, with an investor relations phone contact at +1 (415) 203-6386, as provided in the disclosure for further information and engagement.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 22.0 KB